Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against Mycobacterium tuberculosis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Tuberculosis (TB) remains a serious health issue around the word. Adenovirus (Ad)-based vaccine and modified vaccinia virus Ankara (MVA)-based vaccine have emerged as two of the most promising immunization candidates over the past few years. However, the performance of the homologous and heterologous prime-boost immunization regimens of these two viral vector-based vaccines remains unclear. In the present study, we constructed recombinant Ad and MVA expressing an Ag85B-TB10.4 fusion protein (AdH4 and MVAH4) and evaluated the impact of their different immunization regimens on the humoral and cellular immune responses. We found that the viral vector-based vaccines could generate significantly higher levels of antigen-specific antibodies, IFN-γ-producing splenocytes, CD69+CD8+ T cells, and IFN-γ secretion when compared with bacillus Calmette-Guérin (BCG) in a mouse model. AdH4-containing immunization regimens (AdH4-AdH4, AdH4-MVAH4, and MVAH4-AdH4) induced significantly stronger antibody responses, much more IFN-γ-producing splenocytes and CD69+CD8+ T cells, and higher levels of IFN-γ secretion when compared with the MVAH4-MVAH4 immunization regimen. The number of IFN-γ-producing splenocytes sensitive to CD8+ T-cell restricted peptides of Ag85B (9-1p and 9-2p) and Th1-related cytokines (IFN-γ and TNF-α) in the AdH4-MVAH4 heterologous prime-boost regimen immunization group was significantly higher than that in the other viral vector-based vaccine- and BCGimmunized groups, respectively. These results indicate that an immunization regimen involving AdH4 may have a higher capacity to induce humoral and cellular immune responses against TB in mice than that by regimens containing BCG or MVAH4 alone, and the AdH4-MVAH4 prime-boost regimen may generate an ideal protective effect.
Abstract
Tuberculosis (TB) remains a serious health issue around the word. Adenovirus (Ad)-based vaccine and modified vaccinia virus Ankara (MVA)-based vaccine have emerged as two of the most promising immunization candidates over the past few years. However, the performance of the homologous and heterologous prime-boost immunization regimens of these two viral vector-based vaccines remains unclear. In the present study, we constructed recombinant Ad and MVA expressing an Ag85B-TB10.4 fusion protein (AdH4 and MVAH4) and evaluated the impact of their different immunization regimens on the humoral and cellular immune responses. We found that the viral vector-based vaccines could generate significantly higher levels of antigen-specific antibodies, IFN-γ-producing splenocytes, CD69+CD8+ T cells, and IFN-γ secretion when compared with bacillus Calmette-Guérin (BCG) in a mouse model. AdH4-containing immunization regimens (AdH4-AdH4, AdH4-MVAH4, and MVAH4-AdH4) induced significantly stronger antibody responses, much more IFN-γ-producing splenocytes and CD69+CD8+ T cells, and higher levels of IFN-γ secretion when compared with the MVAH4-MVAH4 immunization regimen. The number of IFN-γ-producing splenocytes sensitive to CD8+ T-cell restricted peptides of Ag85B (9-1p and 9-2p) and Th1-related cytokines (IFN-γ and TNF-α) in the AdH4-MVAH4 heterologous prime-boost regimen immunization group was significantly higher than that in the other viral vector-based vaccine- and BCGimmunized groups, respectively. These results indicate that an immunization regimen involving AdH4 may have a higher capacity to induce humoral and cellular immune responses against TB in mice than that by regimens containing BCG or MVAH4 alone, and the AdH4-MVAH4 prime-boost regimen may generate an ideal protective effect.
참고문헌 (33)
- "Global tuberculosis report 2017"[URL]
- Brewer TF, "Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature", Clin. Infect. Dis., 31, pp.S64~S67 (2000)[DOI]
- Xie Y, "Evaluation of a rapid molecular drug-susceptibility test for tuberculosis", N. Engl. J. Med., 377, pp.1043~1054 (2017)[DOI]
- Triccas JA, "Novel vaccination approaches to prevent tuberculosis in children", Pneumonia (Nathan), 8, pp.18~ (2016)[DOI]
- Bo M, "European policies on tuberculosis prevention in healthcare workers: which role for BCG? A systematic review", Hum. Vaccin. Immunother., 12, pp.2753~2764 (2016)[DOI]
- Mendez-Samperio P, "Global efforts in the development of vaccines for tuberculosis: requirements for improved vaccines against Mycobacterium tuberculosis", Scand. J. Immunol., 84, pp.204~210 (2016)[DOI]
- You Q, "Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis", Int. J. Infect. Dis., 16, pp.e816~e825 (2012)[DOI]
- Dean G, "Effect of dose and route of immunisation on the immune response induced in cattle by heterologous Bacille Calmette-Guerin priming and recombinant adenoviral vector boosting", Vet. Immunol. Immunopathol., 158, pp.208~213 (2014)[DOI]
- Stylianou E, "Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A", Vaccine, 33, pp.6800~6808 (2015)[DOI]
- Minhinnick A, "A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults", Vaccine, 34, pp.1412~1421 (2016)[DOI]
- Nemes E, "Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed bacille Calmette-Guerin for infants of human immunodeficiency virus-infected mothers: a phase 2 randomized, controlled trial", Clin. Infect. Dis., 66, pp.554~563 (2018)[DOI]
- Tye GJ, "Vaccines for TB: lessons from the past translating into future potentials", Clin. Dev. Immunol., 2015, pp.916780~ (2015)
- Billeskov R, "Comparing adjuvanted H28 and modified vaccinia virus Ankara expressing H28 in a mouse and a non-human primate tuberculosis model", PLoS One, 8, pp.e72185~ (2013)[DOI]
- Luabeya AK, "First-in-human trial of the postexposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults", Vaccine, 33, pp.4130~4140 (2015)[DOI]
- Li W, "A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice", Mol. Immunol., 62, pp.86~95 (2014)[DOI]
- Harth G, "Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis", Infect. Immun., 64, pp.3038~3047 (1996)
- Karbalaei Zadeh Babaki M, "Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: biology, immune-pathogenicity, applications in diagnosis, and vaccine design", Microb. Pathog., 112, pp.20~29 (2017)[DOI]
- Lin PL, "The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection", J. Clin. Invest., 122, pp.303~314 (2012)[DOI]
- Agger EM, "Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31", Vaccine, 24, pp.5452~5460 (2006)[DOI]
- 고아라, "Potentiation of Th1-Type Immune Responses to Mycobacterium tuberculosis Antigens in Mice by Cationic Liposomes Combined with De-O-Acylated Lipooligosaccharide", Journal of Microbiology and Biotechnology, 28(1), pp.136~144 (2018), 한국미생물·생명공학회
- Dietrich J, "Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy", J. Immunol., 174, pp.6332~6339 (2005)[DOI]
- Billeskov R, "The HyVac4 subunit vaccine efficiently boosts BCG-primed antimycobacterial protective immunity", PLoS One, 7, pp.e39909~ (2012)[DOI]
- Skeiky YA, "Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen", Vaccine, 28, pp.1084~1093 (2010)[DOI]
- Geldenhuys H, "The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial", Vaccine, 33, pp.3592~3599 (2015)[DOI]
- Kou Y, "Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis", Immunol. Lett., 190, pp.51~57 (2017)[DOI]
- You Q, "Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis", Scand. J. Immunol., 75, pp.77~84 (2012)[DOI]
- Billeskov R, "Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis", Eur. J. Immunol., 40, pp.1342~1354 (2010)[DOI]
- Radosevic K, "Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon", Infect. Immun., 75, pp.4105~4115 (2007)[DOI]
- Rollier CS, "Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses", Vaccine, 34, pp.4470~4474 (2016)[DOI]
- Zeng G, "Th1 cytokines, true functional signatures for protective immunity against TB?", Cell. Mol. Immunol., 15, pp.206~215 (2018)[DOI]
- Pillai VK, "Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines", Vaccine, 29, pp.5399~5406 (2011)[DOI]
- Maeda K, "Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these", Viral Immunol, 18, pp.657~667 (2005)[DOI]
- Betts G, "Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection", PLoS One, 7, pp.e50447~ (2012)[DOI]